Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) |
CVAC-301; CV-301 |
Phase 2 Clinical |
Therion Biologics |
Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma |
Details
|
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) |
|
Phase 2 Clinical |
Guangzhou Anjie Biomedical Technology |
Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Anti-MUC1 monoclonal antibody (OncoQuest) |
AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 |
Phase 2 Clinical |
Altarex |
Pancreatic Neoplasms |
Details
|
Adenoviral MUC1 vaccine (Etubics) |
ETBX-061; Ad5-MUC1 |
Phase 2 Clinical |
Etubics Corp, Immunitybio Inc, Nantkwest Inc |
Chordoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell |
Details
|
GO-2032c |
GO-203-2C |
Phase 2 Clinical |
Genus Oncology Llc, Dana-Farber Cancer Institute |
Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
MUC1-Poly-ICLC |
MUC1-poly-ICLC |
Phase 2 Clinical |
University Of Pittsburgh |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BLP25 liposome vaccine |
BLP-25; L-BLP25; ONO-7165; LP-BLP-25; EMD-531444 |
Phase 2 Clinical |
Cascadian Therapeutics Inc |
Rectal Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
DS-3939 |
DS-3939; DS-3939a |
Phase 2 Clinical |
Daiichi Sankyo Inc |
Solid tumours; Neoplasm Metastasis |
Details
|
BromAc |
|
Phase 2 Clinical |
Mucpharm Pty Ltd |
Coronavirus Disease 2019 (COVID-19); Pneumonia, Ventilator-Associated |
Details
|
BM7PE |
|
Phase 2 Clinical |
Oslo University Hospital |
Colorectal Neoplasms |
Details
|
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney |
Carcinoma, Non-Small-Cell Lung |
Details
|
huMNC2-CAR44 |
huMNC2-CAR44 |
Phase 1 Clinical |
Minerva Biotechnologies |
Breast Neoplasms |
Details
|
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) |
|
Phase 1 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
Gatipotuzumab |
GT-MAB-2.5-GEX |
Phase 1 Clinical |
Nemod, Glycotope Gmbh |
Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
P-MUC1C-ALLO1 |
P-MUC1C-ALLO1; P-MUC1C-101 |
Phase 1 Clinical |
Poseida Therapeutics Inc |
Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
MUC1-peptide-DC-CTL (Beijing Doing Biomedical) |
|
Phase 1 Clinical |
Beijing Doing Biomedical Co Ltd |
Stomach Neoplasms |
Details
|
MUC1-gene-DC-CTL (Beijing Doing Biomedical) |
|
Phase 1 Clinical |
Beijing Doing Biomedical Co Ltd |
Stomach Neoplasms |
Details
|
Recombinant HSP-MUC1 fusion protein (Newsummit) |
|
Phase 1 Clinical |
Shanghai Xinshengyuan Biological Medicine Co Ltd |
Breast Neoplasms |
Details
|
DXC-005 |
DXC-005 |
Phase 1 Clinical |
Hangzhou Dac Biotech Company Ltd |
Solid tumours |
Details
|
M-1231 |
M-1231 |
Phase 1 Clinical |
Emd Serono Research & Development Institute Inc, Merck Serono |
Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
ICTCAR-046 |
ICTCAR-046 |
Clinical |
Innovative Cellular Therapeutics Co Ltd |
Pancreatic Neoplasms |
Details
|
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) |
CVAC-301; CV-301 |
Phase 2 Clinical |
Therion Biologics |
Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma |
Details
|
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) |
|
Phase 2 Clinical |
Guangzhou Anjie Biomedical Technology |
Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Anti-MUC1 monoclonal antibody (OncoQuest) |
AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 |
Phase 2 Clinical |
Altarex |
Pancreatic Neoplasms |
Details
|
Adenoviral MUC1 vaccine (Etubics) |
ETBX-061; Ad5-MUC1 |
Phase 2 Clinical |
Etubics Corp, Immunitybio Inc, Nantkwest Inc |
Chordoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell |
Details
|
GO-2032c |
GO-203-2C |
Phase 2 Clinical |
Genus Oncology Llc, Dana-Farber Cancer Institute |
Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
MUC1-Poly-ICLC |
MUC1-poly-ICLC |
Phase 2 Clinical |
University Of Pittsburgh |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BLP25 liposome vaccine |
BLP-25; L-BLP25; ONO-7165; LP-BLP-25; EMD-531444 |
Phase 2 Clinical |
Cascadian Therapeutics Inc |
Rectal Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
DS-3939 |
DS-3939; DS-3939a |
Phase 2 Clinical |
Daiichi Sankyo Inc |
Solid tumours; Neoplasm Metastasis |
Details
|
BromAc |
|
Phase 2 Clinical |
Mucpharm Pty Ltd |
Coronavirus Disease 2019 (COVID-19); Pneumonia, Ventilator-Associated |
Details
|
BM7PE |
|
Phase 2 Clinical |
Oslo University Hospital |
Colorectal Neoplasms |
Details
|
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney |
Carcinoma, Non-Small-Cell Lung |
Details
|
huMNC2-CAR44 |
huMNC2-CAR44 |
Phase 1 Clinical |
Minerva Biotechnologies |
Breast Neoplasms |
Details
|
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) |
|
Phase 1 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
Gatipotuzumab |
GT-MAB-2.5-GEX |
Phase 1 Clinical |
Nemod, Glycotope Gmbh |
Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
Details
|
P-MUC1C-ALLO1 |
P-MUC1C-ALLO1; P-MUC1C-101 |
Phase 1 Clinical |
Poseida Therapeutics Inc |
Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
MUC1-peptide-DC-CTL (Beijing Doing Biomedical) |
|
Phase 1 Clinical |
Beijing Doing Biomedical Co Ltd |
Stomach Neoplasms |
Details
|
MUC1-gene-DC-CTL (Beijing Doing Biomedical) |
|
Phase 1 Clinical |
Beijing Doing Biomedical Co Ltd |
Stomach Neoplasms |
Details
|
Recombinant HSP-MUC1 fusion protein (Newsummit) |
|
Phase 1 Clinical |
Shanghai Xinshengyuan Biological Medicine Co Ltd |
Breast Neoplasms |
Details
|
DXC-005 |
DXC-005 |
Phase 1 Clinical |
Hangzhou Dac Biotech Company Ltd |
Solid tumours |
Details
|
M-1231 |
M-1231 |
Phase 1 Clinical |
Emd Serono Research & Development Institute Inc, Merck Serono |
Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
ICTCAR-046 |
ICTCAR-046 |
Clinical |
Innovative Cellular Therapeutics Co Ltd |
Pancreatic Neoplasms |
Details
|